Advancing in vitro-in vivo relationships: Steps in establishing an in vitro response for GLP-1 receptor agonists

Following the commercial success of Wegovy® and Ozempic®, pharmaceutical companies are rapidly investing in GLP-1 receptor agonist pipelines. With many candidates in early development stages, reliable in vitro models are critical to guide key decisions in formulation design and lead selection.

In our latest application note, we demonstrate how Pion’s SCISSOR (Subcutaneous Injection Site Simulator) platform can help establish a robust in vitro response for GLP-1 analogues. Using Semaglutide as a model, the study compares in vitro release behavior with known in vivo performance to highlight how SCISSOR can de-risk development early on.

‍